Topic: Imaging

Bladder Cancer Journal Vol. 6, Issue 4

Upregulated FGFR3 signaling in NMIBC and MIBC, the diagnosis and management of checkpoint inhibitor side effects in bladder cancer patients, the etiology of treatment delays in patients receiving neoadjuvant chemotherapy for MIBC, and 25-year trends in stage-specific incidence rates for bladder cancer.

Read More

The Gold Standard for Bladder Cancer Detection

Neal D. Shore, MD, discusses the benefits of using blue light cystoscopy (BLC) in adjunct with white light cystoscopy (WLC) in the diagnosis and treatment of bladder cancers. He then reviews the body of evidence evaluating the accuracy of BLC in detecting significant tumors and briefly compares BLC and narrow band imaging.

Read More

Can MR Imaging Help Triage Bladder Cancer Patients?

John C. Chang, MD, PhD, examines the potential of MRI for staging bladder cancer, emphasizing MRI’s facility in differentiating between muscle invasive and non-muscle invasive bladder cancer (NMIBC). He also acknowledges that MRI scanning can lead to overstaging, and that CT can be effective for detecting higher stages of bladder cancer.

Read More

A Biodynamic Imaging Platform for Bladder Cancer

Jeff Fensterer, Vice President of Marketing Strategy at Animated Dynamics, Inc., introduces a biodynamic imaging platform for bladder cancer that is currently under development. The assay could have clinical utility in selecting patients for neoadjuvant chemotherapy, as well as in treatment planning.

Read More
Loading

Join the GRU Community

- Why Join? -